Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Caris Life Sciences (CAI) Equity Average (2024 - 2025)

Caris Life Sciences has reported Equity Average over the past 2 years, most recently at $527.8 million for Q4 2025.

  • Quarterly results put Equity Average at $527.8 million for Q4 2025, up 121.37% from a year ago — trailing twelve months through Dec 2025 was $527.8 million (up 121.37% YoY), and the annual figure for FY2025 was -$960.8 million, up 58.62%.
  • Equity Average for Q4 2025 was $527.8 million at Caris Life Sciences, up from $465.6 million in the prior quarter.
  • Over the last five years, Equity Average for CAI hit a ceiling of $527.8 million in Q4 2025 and a floor of -$2.5 billion in Q4 2024.